Detailed company information
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Last Updated: Sep 2026
Earnings Transcript for 2024 - Q2Released: Aug 07, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Feb 28, 2024
Earnings Transcript for 2023 - Q3Released: Nov 03, 2023
Earnings Transcript for 2023 - Q2Released: Aug 02, 2023
Earnings Transcript for 2023 - Q1Released: May 05, 2023
Earnings Transcript for 2022 - Q4Released: Feb 22, 2023
Earnings Transcript for 2022 - Q3Released: Nov 02, 2022
Earnings Transcript for 2022 - Q2Released: Aug 04, 2022
Earnings Transcript for 2022 - Q1Released: May 04, 2022
Earnings Transcript for 2021 - Q4Released: Feb 24, 2022
Earnings Transcript for 2021 - Q3Released: Nov 08, 2021
Earnings Transcript for 2021 - Q2Released: Aug 04, 2021
Earnings Transcript for 2021 - Q1Released: May 05, 2021
Earnings Transcript for 2020 - Q4Released: Feb 25, 2021
Earnings Transcript for 2020 - Q3Released: Nov 05, 2020
Earnings Transcript for 2020 - Q2Released: Aug 06, 2020
Earnings Transcript for 2020 - Q1Released: May 07, 2020
Earnings Transcript for 2019 - Q4Released: Feb 26, 2020
Earnings Transcript for 2019 - Q3Released: Nov 12, 2019
Earnings Transcript for 2019 - Q2Released: Aug 06, 2019
Earnings Transcript for 2019 - Q1Released: May 07, 2019
CRBU Caribou Biosciences, Inc.
Dafinchi
